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Edited by Vladimir SkulachevAbstract Tumor necrosis factor a (TNFa), a pleiotropic cyto-
kine, activates both apoptotic and pro-survival signals depending
on the cell model. Using ECV304 cells, which can be made
TNFa-sensitive by cycloheximide (CHX) co-treatment, we eval-
uated the potential roles of ceramide and phospholipase D (PLD)
in TNFa-induced apoptosis. TNFa/CHX induced a robust in-
crease in ceramide levels after 16 h of treatment when cell death
was maximal. PLD activity was increased at early time point
(1 h) whereas both PLD activity and PLD1 protein were
strongly decreased after 24 h. TNFa/CHX-induced cell death
was signiﬁcantly lowered by exogenous bacterial PLD and
phoshatidic acid, and in cells overexpressing PLD1. Conversely,
cells depleted in PLD proteins by small interference RNA (siR-
NA) treatment exhibited higher susceptibility to apoptosis.
These results show that PLD exerts a protective role against
TNFa-induced cell death.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumor necrosis factor a (TNFa) is a pleiotropic cytokine
that exerts various biological eﬀects in diﬀerent cell types. In
numerous tumor cells or virally infected cells, TNFa can initi-
ate an apoptotic cascade that involves a variety of mediators
and regulators including proteases, the sphingolipid ceramide,
and members of the Bcl-2 family. However, most normal cells
including endothelial cells are resistant to TNFa [1–3], but can
be rendered sensitive when protein or RNA synthesis inhibi-
tors such as cycloheximide (CHX) or actinomycin D are asso-Abbreviations: Cer, ceramide; TNFa, Tumor necrosis factor a; PLD,
phospholipase D; PA, phosphatidic acid; DGK, diacylglycerol kinase;
DAG, diacylglycerol; SMase, sphingomyelinase; PBS, phosphate-buf-
fered saline
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doi:10.1016/j.febslet.2006.10.026ciated to TNFa treatment [2,4]. The sensitizing eﬀect of CHX
to TNFa treatment is believed to result from the inhibition of
synthesis of some NF-jB-dependent survival factors [5,6]. The
death induced by TNFa in the presence of CHX shows typical
morphological and biochemical features of apoptosis and is
blocked by anti-apoptotic proteins such as E1B, a viral homo-
logue of Bcl-2 protein [7] or the cowpox virus CrmA protein
[8]. Although the role of ceramide as a second messenger in
apoptosis signaling has been a matter of debate, its involve-
ment in the transmission of the death signal initiated by
TNF receptor activation is now well recognized. In diﬀerent
cell types, TNFa has been shown to increase intracellular cer-
amide levels either through the activation of sphingomyelin-
ases (SMases) or by a mechanism involving de novo
ceramide synthesis [9–11].
On the other hand, phospholipase D (PLD) through its reac-
tion product, phosphatidic acid (PA), has been shown to play a
key role in the proliferation of various cell models, and there is
a growing body of evidence linking PLD activity with mito-
genic signaling. Thus, PLD activity has been shown to increase
in response to various growth factors and in cells transformed
by a variety of oncogenes [12]. However, the role of PLD in
apoptosis remains controversial, both pro- and anti-apoptotic
eﬀects being reported depending on the cell type and the apop-
totic stimulus considered [13,14]. Indeed, some reports indi-
cated that PLD activity is upregulated during apoptosis of
hematopoietic cells such as Jurkat T-cells [15] and murine B
lymphoma A20 cells [16] or normal rat ﬁbroblasts [17]. Con-
versely, a downregulation of PLD has been reported to occur
during the ceramide-induced apoptosis of rat C6 glial cells [18]
and the human keratinocyte cell line HaCaT [19]. Interestingly,
recent studies are beginning to point out a protective role of
PLD against apoptosis of either normal [20,21] or transformed
cells [22,23] induced by diﬀerent stimuli.
In the present study, we set out to investigate whether cera-
mide and PLD were involved in TNFa-induced apoptosis of
ECV304 cells, a model of TNFa-resistant cells, which can be
made TNFa-sensitive by CHX co-treatment. We ﬁrst investi-
gated the involvement of ceramide in the apoptotic response
to TNFa/CHX. Then, we examined whether the apoptotic re-
sponse of ECV304 cells to TNFa could be modiﬁed by changes
in their PLD activity or PA content. PLD activity increases
were mimicked either by addition of exogenous bacterial
PLD or PA, or through PLD1 and PLD2 overexpression,
whereas 1-butanol which prevents normal PLD functioning
and PLDI- and PLD2-siRNA were used to lower endogenous
PLD activity. Herein, our data provide evidence that PLD has
a survival role counteracting TNFa-induced cell death in
ECV304 cells.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
TNFa was from Peprotech (AbCys, Paris, France). Triton X-100
was from Pierce. Silica Gel G60 and LK6D Silica Gel G60 (Whatman)
TLC plates were from VWR International (Fontenay-sous-Bois,
France). [33P]-ATP, [3H]-palmitic acid, MP Hyperﬁlm, ECL were from
Amersham Biosciences (Orsay, France). HRP-conjugated anti-mouse
IgG antibody was from Jackson Immunoresearch Laboratories
(Soham, UK). Bradford protein assay and HRP-conjugated anti-
rabbit IgG antibody were from Bio Rad (Marnes-La-Coquette,
France). Immobilon P membranes were from Millipore (St Quentin
Yvelines, France). Annexin V-conjugated Alexa Fluor 594 was from
Molecular Probes. Phospholipase D from Streptomyces chromofuscus,
L-a dipalmitoyl and L-a dioctanoyl phosphatidic acids (sodium salts),
anti a-tubulin monoclonal antibody were from Sigma–Aldrich (L’Isle
d’Abeau, France). Escherichia coli DAG Kinase and cycloheximide
were from Calbiochem (Merck Biosciences, France). TransPEI trans-
fection reagent and negative control siRNA were from Eurogentec
(Anger, France). C2-ceramide and dihydroceramide were purchased
from Avanti Polar Lipids (Biovalley, France).
2.2. Cell culture
ECV-304, an immortalized human vascular endothelial cell line, was
obtained from American Type Culture Collection (Rockville, MD).
Cells were grown in M199 medium supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 U/ml penicillin and 100 lg/ml strepto-
mycin, in 5% CO2 at 37 C in a humidiﬁed incubator. Treatments were
carried out on 80–90% conﬂuent cells.
2.3. Cell viability assay
Viability of cultured cells was measured at various time points using
the trypan blue exclusion test or the MTT colorimetric assay (Roche
Diagnostics, Meylan, France) as described previously by Mosmann
[24]. In this latter case, cells were cultured in 96-well culture plates at
a cell density of 105 cells/ml. At the end of the treatment period in ab-
sence or presence of TNFa or TNFa/CHX, 10 ll of the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) labeling
reagent (0.5 mg/ml ﬁnal concentration) was added to each well. The
cells were incubated for further 4 h. 100 ll solubilization solution
was then added and plates were allowed to stand overnight at 37 C
in a humidiﬁed atmosphere. The optical density (OD) was measured
the next day at 550 and 690 nm wavelength using an ELISA plate read-
er (PowerWave X, Biotek Instruments, Winooski, USA). The number
of viable cells was directly correlated to the diﬀerence of absorbance
measured at 550 and 690 nm. Results were normalized relative to their
respective controls (without TNFa or TNFa/CHX) taken as 100. In
some experiments, apoptosis was ascertained by annexin-V binding.
After treatment, cells were washed once with PBS then incubated with
1 lg/ml annexin-V conjugated to Alexa Fluor 594 (Molecular Probes)
in annexin-binding buﬀer (10 mM HEPES, pH 7.4, 140 mM NaCl and
2.5 mM CaCl2) at 37 C. After 30 min of incubation, cells were exam-
ined by ﬂuorescence microscopy and counted for annexin-V binding.
Diﬀerent ﬁelds (at least 300 cells) were counted for each experiment.
2.4. Ceramide measurement
ECV 304 cells cultured in 10 cm Petri dishes were treated for the
indicated times with TNFa in the presence or absence of CHX. Culture
medium was removed and centrifuged to collect ﬂoated dead cells. At-
tached cells were washed twice with ice-cold PBS, scraped in 1 ml
methanol, and pooled with pelleted ﬂoating cells. Total lipids were
then extracted by the method of Bligh and Dyer [25]. Lipids were then
dried and an aliquot was taken from each sample for total lipid phos-
phate determination as described [26]. Measurement of ceramide levels
was performed using the DAG kinase assay as previously described
[26,27]. Brieﬂy, lipid samples and standards were sonicated in 20 ll
of mixed micelles (7.5% b-n-octyl-D-glucopyranoside/25 mM dioleyl
phosphatidylglycerol) and incubated for 30 min at 37C. Then, 70 ll
of enzyme reaction buﬀer (75 mM imidazole pH 6.6, 71 mM LiCl,
17.8 mM MgCl2, 1.5 mM EGTA, 0.25 mM DTPA, 2.8 mM DTT
and 3 lg E. coli DAG kinase) and 10 ll of ATP mixture (10 mM
ATP and 0.2 lCi/ll [c-33P]ATP in 5 mM imidazole) was added to sam-
ples, and the mixture incubated for 1 h at room temperature. Phos-
phorylated ceramide and DAG were extracted with chloroform/methanol. Lipid extracts, DAG and ceramide standards (0–600 pmol)
were then spotted onto TLC plates and developed in chloroform/ace-
tone/methanol/acetic acid/ water (50:20:15:10:5, by volume). Radioac-
tive PA and ceramide-1-P were visualized and quantiﬁed by
autoradiography.
2.5. PLD assay in intact cells
PLD was determined on the basis of its transphosphatidylation
activity. As it is known that serum starvation increases ceramide levels,
ECV304 cells were labeled in complete medium containing 2 lCi/ml
[3H]-palmitic acid for 24 h at 37 C. Cells were then washed twice with
PBS, shifted to complete culture medium and treated for the indicated
times with CHX or with TNFa plus CHX; 1-butanol (1% ﬁnal concen-
tration) was added during the last 30 min of treatment. Cells were then
collected and lipids extracted by the method of Bligh and Dyer in the
presence of 50 lM butylhydroxylated toluene. Phosphatidylbutanol
was separated by bidimensional TLC using chloroform/methanol/
28% ammonia (65:35:5.5, by volume) for the ﬁrst migration, and ethyl
acetate/isooctane/acetic acid (9:5:2, by volume) for migration in the
second dimension. TLC plates were then stained with Coomassie Bril-
liant Blue R and phosphatidylbutanol spots were scraped oﬀ and the
radioactivity determined by liquid scintillation counting. Radioactivity
associated with phosphatidylbutanol was expressed as percentage of
total phospholipid radioactivity.
2.6. Transient transfections
pEGFP-PLD1b and -PLD2 constructs were prepared as previously
described [28]. Transient transfections using transPEI reagent were
performed according to the manufacturer’s recommendations. Brieﬂy,
transPEI reagent diluted in 150 mM NaCl was mixed with 4.5 lg
pEGFP-PLDI or pEGFP-PLD2 DNA and left in contact for
30 min. The mix was then added dropwise to 3 · 105 cells suspended
in 4.5 ml of complete culture medium. The cells were plated
(105 cells/well) and cultured for 12 h in complete culture medium be-
fore TNFa or TNFa/CHX treatment for an additional 9 h period.
Control cells were transfected with 4.5 lg of pEGFP DNA (empty vec-
tor) in the same experimental conditions. SiRNA for PLD1 (hPLD1
target sequence: AAGTTAAGAGGAAATTCAAGC) and siRNA
for PLD2 (hPLD2 target sequence: GACACAAAGTCTTGATGAG)
were designed according to Fang et al. [29] and Powner et al. [30],
respectively. A siRNA without sequence similarity with any known
mammalian gene was used as a negative control. Transfection of siR-
NA was performed using Xtreme Gene reagent (Roche) with 25 nM
siRNA in antibiotic-free medium. The cells were kept for 12 h in this
medium and then shifted to complete culture medium for 24 h before
treatment with TNFa/CHX.
2.7. Western blotting experiments
Cells were homogenized in 20 mM Tris/HCl, pH 7.6, buﬀer contain-
ing 100 mMNaCl, 1% Triton, and protease inhibitors cocktail. Cell ly-
sates were mixed with Laemmli buﬀer supplemented with 2 M urea,
boiled for precisely 1 min, and separated on 8% SDS–polyacrylamide
gel including 4 M urea. The blots were probed with PLD1- and
PLD2-speciﬁc polyclonal antibodies kindly provided by Dr S. Bourg-
oin (Laval University, Canada), diluted 1:2000. Immunoblots were re-
vealed with the ECL detection system. After stripping, the membranes
were reprobed with an anti-a-tubulin monoclonal antibody for nor-
malization. Proteins were assayed by Bradford method.
2.8. Statistical analysis
Data were compared by ANOVA (Statview II for Macintosh) fol-
lowed by protected t test for multiple comparison. Paired sample
means were compared using the t test. P values of 0.05 or less were
considered statistically signiﬁcant.3. Results and discussion
3.1. Cytotoxic eﬀects of TNFa/CHX in ECV304 cells
TNFa has been shown to induce apoptotic signals together
with the activation of survival pathways [31,32]. The survival
pathways induced by TNFa are known to require de novo
6226 H. Birbes et al. / FEBS Letters 580 (2006) 6224–6232protein synthesis, and blocking protein synthesis render the
cells sensitive to TNFa-induced cell death [11]. Treatment of
ECV304 cells for up to 24 h with TNFa (200 ng/ml) alone
did not induce any cell death (Fig. 1A and B) showing that
although ECV304 are immortalized cells, they are spontane-
ously resistant to the cytotoxic eﬀects of TNFa. We thus con-
sidered to evaluate TNFa cytotoxicity in the absence of
protein synthesis, and as a preliminary step, we addressed
the eﬀects of cycloheximide on protein synthesis in ECV304
cells. [3H]-leucine incorporation was inhibited in a dose-depen-
dent manner when ECV304 cells were treated with CHX. At a
concentration of 10 lg/ml, CHX markedly inhibited [3H]-leu-
cine incorporation by around 97.5% (data not shown) but
did not induce any cell death (Fig. 1B). In contrast, when cells
were treated with increasing concentrations of TNFa in the
presence of 10 lg/ml CHX, a dose-dependent decrease of cell
survival was observed (Fig. 1A). The percentage of live cells
decreased to approximately 25% of control after 24 h of treat-
ment with the combination of TNFa (200 ng/ml) and CHX
(10 lg/ml) as measured by MTT assay. Time-course studies
showed that cell death induced by the combination of TNFaTNFα(ng/ml)
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Fig. 1. Eﬀect of TNFa/CHX on ECV304 cell death. (A). ECV304 cells were e
of CHX (10 lg/ml) for 24 h. Cell survival was determined by MTT assay.
signiﬁcant diﬀerence (P < 0.05) as compared with TNFa alone. (B) EVC-304
(10 lg/ml) for the indicated periods of times. Cell death was determined by try
separate experiments. (C) ECV304 cells were treated as in B and cell death w
condition, the percentage of annexin-V labeled cells was determined in at leand CHX started from 6 h (around 15%) and reached a max-
imum at 16 h (around 75%), as evaluated by trypan blue exclu-
sion test (Fig. 1B). Cells undergoing apoptosis present
characteristic features, such as phosphatidylserine (PS) exter-
nalization, an early event in apoptosis. The presence of PS in
the outer leaﬂet of ECV304 cell membrane was thus evaluated
by means of speciﬁc PS labeling with annexin-V conjugated to
a ﬂuorescent dye. After 6 h of treatment with the combination
of TNFa and CHX, the proportion of annexin-V labeled cells
was markedly higher (around 30%) than the proportion of cells
excluding the blue dye (Fig. 1C). This result indicates that, at
this early time point, around half of cells with externalized PS
were still alive. When cells were treated with TNFa or CHX
alone the percentage of annexin-V positive cells remained low-
er than 7%, whatever the duration of treatment, and similar to
that measured in untreated cells (Fig. 1C).
3.2. Eﬀect of TNFa/CHX on ceramide levels
TNFa is known to increase the intracellular levels of cera-
mide during apoptosis in a number of cell types [9,10,27].
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absence or presence of CHX (10 lg/ml) for the indicated periods of times. At the end of treatment, lipids were extracted and ceramide levels were
measured using the DGK assay as described in Section 2. Results are means ± S.E. of ﬁve to six independent experiments. The inset shows the early
time points of ceramide production.  indicates a signiﬁcant diﬀerence (P < 0.05) as compared with TNFa alone. (B) ECV304 cells were treated with
increasing concentrations of C2-ceramide (0–100 lM) for 24 h and cell death was measured by trypan blue exclusion assay. (C) ECV304 cells were
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control cells (Fig. 2A). In contrast, TNFa plus CHX treatment
caused a biphasic increase of ceramide levels. A ﬁrst and mod-
est increase of ceramide level (1.5-fold) was observed at 6 h
(Fig. 2A, inset). At later time points, a robust increase of cer-
amide levels was observed, which reached a maximum at 16 h.
3.3. Eﬀect of exogenous ceramide on ECV304 cell death
The involvement of ceramide in ECV304 cell apoptosis in-
duced by TNFa/CHX was further explored using a cell perme-
able ceramide. As shown in Fig. 2B, treatment of ECV304 cells
with C2-ceramide for 24 h, at concentrations ranging from 10
to 100 lM caused a dose-dependent cell death, with around
75% of the cells undergoing death at 100 lM. Apoptosis was
also evaluated by assessment of annexin-V binding (Fig. 2C).
In these experiments, 40% of cells treated with 75 lM C2-cer-
amide underwent apoptosis. As a control, the eﬀect of the bio-logically inactive ceramide precursor, C2-dihydroceramide,
was also evaluated. No signiﬁcant pro-apoptotic eﬀect was
found at concentrations up to 75 lM (Fig. 2C). These results
indicate that C2-ceramide was able to induce apoptosis of
ECV304, suggesting that cell death induced by TNFa/CHX
could be mediated, at least partly, through the observed cera-
mide generation.
3.4. Eﬀect of TNFa/CHX and exogenous ceramide on PLD
activity and expression
We next investigated whether PLD activity and expression
were modiﬁed after 1, 6, and 24 h of treatment with 200 ng/
ml TNFa in the presence of 10 lg/ml CHX. After 1 h of treat-
ment, a time point when neither ceramide level nor cell survival
was aﬀected, PLD activity was signiﬁcantly increased (+40%,
P < 0.02) as compared to cells incubated with CHX alone
(Fig. 3B). After 6 h, which corresponds to the ﬁrst modest
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trol level, whereas a marked fall (61%, P < 0.002) was ob-
served at 24 h when both ceramide increase and cell death
were maximal (Fig. 3B). No signiﬁcant variations of PLD
activity were observed either in untreated cells or cells treated
with TNFa alone at any time point (not shown). As illustrated
on the representative blots shown in Fig. 3A, the large decrease
in PLD activity observed after 24 h of treatment with TNFa/
CHX could be attributed to a marked reduction of PLD1
expression (57%, P < 0.02) as compared to levels observed
in CHX treated cells, as indicated by ANOVA analysis of den-
sitometric evaluation from three separate experiments (not
shown). No signiﬁcant variation of PLD1 expression could
be detected in untreated cells or cells treated by TNFa alone.
PLD2 expression remained unchanged whatever the nature
and duration of cell treatment (Fig. 3A, quantiﬁcation not
shown). In addition, a direct inhibition of PLD activity by in-
creased ceramide levels could also be involved at this later time
point. Indeed, ceramide has been reported to inhibit PLD
activity both in cell-free systems [33] and in intact cells [34].
In the present study, we observed that PLD activity of
ECV304 cells was highly sensitive to C2-ceramide inhibition
(50% and 75% inhibition at 50 and 75 lM, respectively,Fig. 3D) whereas dihydro C2-ceramide was inactive. Further-
more, as shown in Fig. 3C, C2-ceramide also reduced PLD1
expression of ECV304 cells after 24 h of treatment (43 and
49% at 50 and 75lM, respectively, P < 0.01, quantiﬁcation
not shown). This suggests that ceramide could act both by
inhibiting PLD activity and decreasing the expression of the
PLD1 isoform. On the whole, these results show that as long
as PLD activity was maintained elevated, apoptosis did not oc-
cur and suggest that PLD activity exerted a protective eﬀect
against apoptosis in ECV304 cells.
3.5. Eﬀect of PLD on TNFa/CHX-induced cell death
To explore further the potential protective role of PLD in
ECV304 cells, we investigated the eﬀect of exogenous addition
of a bacterial PLD from Streptomyces chromofuscus (scPLD)
on TNFa/CHX-induced cell death. Exogenous scPLD has
been shown to eﬃciently protect neutrophils from spontaneous
as well as FAS-induced apoptosis [21] and to inhibit hypoxia-
induced apoptotic cell death in PC12 cells [35]. Addition of
scPLD to ECV304 cells prior to treatment with 20 ng/ml
TNFa in the presence of 10 lg/ml CHX signiﬁcantly decreased
TNFa/CHX death promoting eﬀect, as shown by the dose-
dependent increase of cell survival measured by the MTT assay
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has a protective eﬀect against apoptosis although we cannot
exclude a contributing eﬀect of other bioactive lipids, due to
the limited speciﬁcity of scPLD toward phosphatidylcholine.
The protective eﬀect of PA was supported further by results
of experiments showing that addition of dipalmitoyl PA
(di-C16-PA) or the cell-permeant dioctanoyl PA (di-C8-PA)
signiﬁcantly increased cell survival to TNFa/CHX treatment
(Fig. 4B and C). Moreover, the protective eﬀect of 100 lM
di-C8-PA was further increased by propranolol, which pre-
vents PA dephosphorylation by PA phosphohydrolase and
then enhances PA accumulation. These results together with
the lack of eﬀect of the DAG kinase inhibitor R59022 (data
not shown) suggest that PA itself, rather than PA derived
metabolites, protects ECV 304 cells against TNFa/CHX-in-
duced cell death.
To conﬁrm that PLD has an anti-apoptotic eﬀect in ECV304
cells, we transiently overexpressed GFP-PLD1 and -PLD2
fusion proteins prior to TNFa/CHX treatment of the cells.
The eﬃciency of transfection estimated by observing the bright
ﬂuorescence of transfected cells was similar for both vectors
(around 20%). Transient overexpression of both fusion pro-
teins signiﬁcantly increased PLD activity as compared to cells
transfected with the empty vector harboring only GFP
(Fig. 5A). ECV304 cells overexpressing PLD1 (Fig. 5B) exhib-
ited a higher percentage of live cells than cells transfected with
the empty vector (P < 0.05). Cells overexpressing PLD2 exhib-ited a similar trend although diﬀerence with the empty vector
did not reach signiﬁcance (P = 0.1). The lower protective eﬀect
of overexpressed PLD2 can hardly be explained by a lower
transfection eﬃciency because the percentages of PLD1- and
PLD2-transfected cells were very similar. It may be speculated
that overexpressed PLD2, but not PLD1, would be partially
mislocated with respect to the endogenous protein. Although
fully catalytically active, mislocated PLD2 might have im-
paired protective eﬀects or might have trapped endogenous
activators, thus preventing the correctly located PLD2 to be
functional. We next examined whether PLD inhibition by 1-
butanol could potentiate the apoptotic eﬀect of TNFa/CHX,
using a suboptimal concentration of TNFa (0.2 ng/ml), which
only gave minimal cell death in the presence of 10 lg/ml CHX.
Given the transphosphatidylation property of PLD, the use of
a primary alcohol is a convenient way to divert phosphatidic
acid synthesis toward that of the biologically inactive phos-
phatidylalcohol, and thus to mimic PLD inhibition. As shown
in Fig. 5C, addition of 0.5% 1-butanol to ECV304 cells prior to
treatment with TNFa/CHX for 24 h, markedly decreased cell
survival. Control treatment by 2-butanol, an isomer not recog-
nized by PLD, had no eﬀect on TNFa/CHX-induced cell
death, which rules out non speciﬁc eﬀects of alcohol treatment.
Finally, in a more straightforward approach, we examined the
eﬀect of PLD1 and PLD2 knockdown by means of speciﬁc
siRNA on TNFa/CHX-induced cell death. As shown in
Fig. 5E, both PLD1- and PLD-2 siRNA reduced the level of
vector PLD1 PLD2
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Fig. 5. Eﬀect of changes in PLD activity on TNFa/CHX-induced cell death. (A and B) ECV304 cells were transiently transfected with pEGFP-
PLD1, -PLD2 and empty vector as described in Section 2. In (A), PLD activity was measured as described in the legend of Fig. 4. The radioactivity of
phosphatidylbutanol was expressed in percent of radioactivity of total phospholipids. Results are means ± S.E. of three separate experiments. 
signiﬁcantly diﬀerent from empty vector, P < 0.05. In (B), transfected cells were treated with 20 ng/ml TNFa in the presence of 10 lg/ml CHX for
16 h, or left untreated, and cell viability was measured by the MTT assay. Results are expressed relative to cell survival measured in the absence of
TNFa/CHX taken as 100. They are means ± S.E. of three separate experiments performed with six replicates.  signiﬁcantly diﬀerent from empty
vector, P < 0.05. (C) ECV304 cells were incubated in the absence or presence of either 1-butanol or 2-butanol (0.5% ﬁnal concentration) for 10 min
before addition of 0.2 ng/ml TNFa in the presence or absence of 10 lg/ml CHX for 24 h. Cell viability was determined by MTT assay. Results are
expressed relative to cell survival measured in the absence of TNFa or TNFa/CHX taken as 100. They are means ± S.E. of two separate experiments
performed with six replicates.  signiﬁcantly diﬀerent from TNFa/CHX without butanol, P < 0.05. (D) ECV304 cells were transfected with negative
control siRNA (ctl siRNA), with PLD1- or PLD2-siRNA or left untreated and then stimulated with 20 ng/ml TNFa in the presence of 10 lg/ml CHX
for 16 h. Cell death was measured by annexin-V binding assay. For each condition, the percentage of annexin-V labeled cells was determined in at
least 10 diﬀerent ﬁelds.  signiﬁcantly diﬀerent from control siRNA, P < 0.05. (E) ECV304 cells were transfected with PLD1- or PLD2-siRNA or left
untreated, then lysed and subjected to Western blot analyses with anti-PLD1 or anti-PLD2 antibodies. Blots were reprobed with anti a-tubulin
antibody.
6230 H. Birbes et al. / FEBS Letters 580 (2006) 6224–6232the corresponding PLD proteins by around 80%. PLD1 as well
as PLD2 silencing signiﬁcantly increased cell death measured
by annexin-V labeling as compared to untreated cells or to
cells transfected with the negative control siRNA (Fig. 5D).In conclusion, an increase of ceramide level and a concomi-
tant inhibition of PLD activity/expression were observed in the
course of ECV304 cell death induced by TNFa/CHX. The
present results showing that both exogenous bacterial PLD
H. Birbes et al. / FEBS Letters 580 (2006) 6224–6232 6231and PLD overexpression counteract TNFa-induced apoptosis,
and that depleting PLD proteins strongly potentiates cell
death, bring strong support to a role of PLD activity as a sur-
vival pathway in TNFa/CHX-treated cells. Although the func-
tional connexion between PLD1 and cell survival remains to be
determined, several hypotheses can be envisaged to explain the
pro-survival eﬀect of the PLD product, PA. Among the vari-
ous PA targets identiﬁed to date, sphingosine kinase-1 (SK1)
is of special interest due to its key role in regulating the balance
between pro- and anti-apoptotic sphingolipids [36]. SK1 has
been shown to translocate to PA-enriched membranes upon
cell stimulation, the translocation being accompanied by a
marked activation [37]. Thus, increasing PA level in ECV304
cells might result in an increased level of the pro-survival
S1P at the expense of ceramide/sphingosine. The mammalian
target of rapamycin mTOR is another PA-activated protein
which plays a crucial role in the commitment of cells to life
or death [38]. Thus, PLD-dependent mTOR activation is con-
sidered to provide survival signals in most cancer cells [39].
The fact that TNFa/CHX-induced cell death was markedly
increased by rapamycin in ECV304 cells (our unpublished
results) suggests that the latter pathway may be involved in
the protection of ECV304 cells against apoptosis.
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